ALLKのチャート
ALLKの企業情報
| symbol | ALLK |
|---|---|
| 会社名 | Allakos Inc （アラコス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 Allakos Inc. is a clinical-stage biotechnology company which is engaged in developing antibodies that selectively target mast cells and eosinophils. The Company's antibodies target receptor molecules present on the surface of immune effector cells which are involved in allergy inflammation and tissue damage. Its lead program is AK002 which is an antibody that targets Siglec-8 an inhibitory receptor found on eosinophils and mast cells. The Company's AK002 is used in the treatment of various diseases with abnormal proliferation of mast cells including eosinophilic gastritis (EG) indolent systemic mastocytosis urticaria and allergic conjunctivitis. アラコスは米国のバイオ医薬品企業。臨床段階で、アレルギ―性疾患、炎症性疾患および増殖性疾患の治療用抗体の開発に従事する。同社は、好酸球性胃炎および胃腸炎、じんま疹、無症候性全身性肥満細胞症、重度のアレルギ―性結膜炎の治療薬AK002を開発する。本社所在地はカリフォルニア州サン・カルロス。 |
| 本社所在地 | 75 Shoreway Road Suite A San Carlos CA 94070 USA |
| 代表者氏名 | Christopher Bebbington Christopher Bebbington |
| 代表者役職名 | President Founder Director |
| 電話番号 | +1 650-597-5002 |
| 設立年月日 | 40969 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2018年 |
| 従業員数 | － |
| url | www.allakos.com |
| nasdaq_url | https://www.nasdaq.com/symbol/allk |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -30.66500 |
| 終値（lastsale） | 32.035 |
| 時価総額（marketcap） | 1349091845.065 |
| 時価総額 | 時価総額（百万ドル） 1485.749 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 1564.622 |
| 当期純利益 | 当期純利益（百万ドル） -31.66600 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Allakos Inc revenues was not reported. Net loss increased 83% to $17.9M. Higher net loss reflects Research and Development - Balancing increase of 64% to $13.2M (expense) General and Administrative - Balancing increase from $1.4M to $4M (expense) Stock-based Compensation in SGA increase from $86K to $718K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$0.24 to -$0.43. |
ALLKのテクニカル分析
ALLKのニュース
The Daily Biotech Pulse: FDA Nod For Amphastar's Generic Glucagon, Arcturus Sinks On Vaccine Data, Decision Day For Osmotica 2020/12/29 13:09:37 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 28) Aclaris Therapeutics Inc (NASDAQ: ACRS ) Allakos Inc (NASDAQ: ALLK ) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arvinas Inc (NASDAQ: ARVN ) Atea Pharmaceuticals, Inc. (NASDAQ: AVIR ) AtriCure Inc. (NASDAQ: ATRC ) BIO-TECHNE Corp (NASDAQ: TECH ) BridgeBio Pharma Inc (NASDAQ: BBIO ) Cellectis SA (NASDAQ: CLLS ) Crispr Therapeutics AG (NASDAQ: CRSP ) Curis, Inc. (NASDAQ: CRIS ) Edwards Lifesciences Corp (NYSE: EW ) ESSA Pharma Inc (NASDAQ: EPIX ) Eton Pharmaceuticals Inc (NASDAQ: ETON ) Evelo Biosciences Inc (NASDAQ: EVLO ) Evogene Ltd (NASDAQ: EVGN ) Inari Medical Inc (NASDAQ: NARI ) Integra Lifesciences Holdings Corp (NASDAQ: IART ) Intellia Therapeutics Inc (NASDAQ: NTLA ) Jazz Pharmaceuticals PLC (NASDAQ: JAZZ ) Kodiak Sciences Inc (NASDAQ: KOD ) Kymera Therapeutics Inc (NASDAQ: KYMR ) Lumos Pharma Inc (NASDAQ: LUMO ) Medicenna Therapeutics Corp (NASDAQ: MDNA ) Myovant Sciences Ltd (NYSE: MYOV ) - announced a licensing deal with Pfizer Inc.
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020 2020/10/27 23:56:59 GlobeNewswire
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing…
Allakos (NASDAQ:ALLK) Stock Rating Lowered by Zacks Investment Research 2020/10/23 05:32:44 Dakota Financial News
Allakos (NASDAQ:ALLK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based […]
Why Allakos (ALLK) Stock Might be a Great Pick 2020/05/15 13:02:00 Zacks Investment Research
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
All You Need to Know About Allakos Inc (ALLK) Rating Upgrade to Buy 2020/05/14 16:00:06 Zacks Investment Research
Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020 2020/10/27 23:56:59 GlobeNewswire
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing…
Allakos (NASDAQ:ALLK) Stock Rating Lowered by Zacks Investment Research 2020/10/23 05:32:44 Dakota Financial News
Allakos (NASDAQ:ALLK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based […]
Why Allakos (ALLK) Stock Might be a Great Pick 2020/05/15 13:02:00 Zacks Investment Research
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
All You Need to Know About Allakos Inc (ALLK) Rating Upgrade to Buy 2020/05/14 16:00:06 Zacks Investment Research
Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ALLAKOS FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Allakos Inc. Investors of Deadline Today In Securities Class Action First Filed by Firm – ALLK 2020/05/11 14:03:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Allakos investors under the federal securities laws. To join the Allakos class action, go to http://www.rosenlegal.com/case
Allakos Previews Preliminary Financial Results for the Three Months Ended September 30, 2020 2020/10/27 23:56:59 GlobeNewswire
REDWOOD CITY, Calif., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK) (“Allakos” or “the Company”), a biotechnology company developing…
Allakos (NASDAQ:ALLK) Stock Rating Lowered by Zacks Investment Research 2020/10/23 05:32:44 Dakota Financial News
Allakos (NASDAQ:ALLK) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Allakos Inc. is a clinical stage bio-technology company. It discovers and develops therapeutic antibodies for the treatment of allergic, inflammatory and proliferative diseases. Allakos Inc. is based […]
Why Allakos (ALLK) Stock Might be a Great Pick 2020/05/15 13:02:00 Zacks Investment Research
Allakos (ALLK) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
All You Need to Know About Allakos Inc (ALLK) Rating Upgrade to Buy 2020/05/14 16:00:06 Zacks Investment Research
Allakos Inc (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ALLAKOS FINAL DEADLINE TODAY: ROSEN, A GLOBALLY RECOGNIZED FIRM, Reminds Allakos Inc. Investors of Deadline Today In Securities Class Action First Filed by Firm – ALLK 2020/05/11 14:03:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allakos Inc. (NASDAQ: ALLK) between August 5, 2019 through December 17, 2019, inclusive (the “Class Period”) of the important May 11, 2020 lead plaintiff deadline in the securities class action commenced by the firm. The lawsuit seeks to recover damages for Allakos investors under the federal securities laws. To join the Allakos class action, go to http://www.rosenlegal.com/case